Icatibant Teva

Icatibant acetate, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with a confirmed diagnosis, providing rapid reduction of swelling and pain.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is manufactured to EU standards and distributed under strict quality controls to ensure consistency across global markets.

Icatibant Teva is a bradykinin B2 receptor antagonist that acts on the kallikrein‑kinin system to treat hereditary angioedema.

Acute hereditary angioedema attacks (type I and II): rapid reduction of subcutaneous and submucosal swelling, alleviating pain and preventing airway obstruction.

Icatibant Teva may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: discomfort at the injection site. - Erythema: redness around the injection area. - Local swelling: mild edema at the site. - Pruritus: itching at or near the injection site. - Nausea: occasional upset stomach. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypersensitivity: rash, bronchospasm, or angioedema unrelated to HAE. - Hypotension: sudden drop in blood pressure, potentially causing dizziness or fainting.

Before using Icatibant Teva, consider the following safety measures.

Assess hypersensitivity: verify no known allergy to icatibant or formulation components. Monitor cardiovascular status: observe for hypotension or tachycardia after injection. Use caution in renal or hepatic impairment: adjust monitoring as needed. Avoid concomitant ACE inhibitors: increased risk of angioedema. Educate patients on self‑administration: ensure proper injection technique and site rotation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Teva has limited drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and heighten angioedema risk. - Other bradykinin B2 antagonists: concurrent use can reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may influence hereditary angioedema severity. - C1‑esterase inhibitor concentrates: may alter the clinical response when used together. - Antihistamines: monitor for additive effects on blood pressure.